Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P03928
UPID:
ATP8_HUMAN
Alternative names:
A6L; F-ATPase subunit 8
Alternative UPACC:
P03928; Q34771
Background:
ATP synthase protein 8, also known as A6L and F-ATPase subunit 8, plays a crucial role in cellular energy production. It is a minor subunit of the mitochondrial membrane ATP synthase (Complex V), which synthesizes ATP from ADP, utilizing a proton gradient generated by the respiratory chain. This process is essential for a wide range of cellular functions.
Therapeutic significance:
Mutations in ATP synthase protein 8 are linked to mitochondrial complex V deficiency, mitochondrial 2, and infantile hypertrophic cardiomyopathy. These conditions highlight the protein's critical role in mitochondrial function and cardiac health, suggesting that targeting ATP synthase protein 8 could lead to novel treatments for mitochondrial disorders and cardiomyopathies.